Verastem (VSTM) Operating Income (2011 - 2026)
Verastem's (VSTM) quarterly Operating Income came in at -$44.9 million in Q1 2026, down 1.64% year-on-year from -$45.6 million in Q1 2025, and down 8.25% quarter-over-quarter from -$41.5 million in Q4 2025.
Verastem (VSTM) Operating Income (2011 - 2026) Analysis & Trends
Verastem's Operating Income history runs 16 years deep, the most recent figure standing at -$44.9 million for Q1 2026.
- On a quarterly basis, Operating Income fell 1.64% year-over-year to -$44.9 million in Q1 2026; TTM through Mar 2026 was -$170.9 million, a 30.35% decrease from a year earlier, with the FY2025 full-year figure at -$170.1 million, down 47.99% from the prior year.
- Operating Income slipped to -$44.9 million in Q1 2026 per VSTM's latest filing, from -$41.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$16.8 million in Q4 2022 and bottomed at -$44.9 million in Q1 2026.
- The 5-year median for Operating Income is -$28.1 million (2024), against an average of -$29.1 million.
- Across the five-year window, Operating Income increased 9.93% in 2024 and tumbled 139.45% in 2025, its largest moves.
- Year by year, Operating Income stood at -$16.8 million in 2022, then sank by 84.85% to -$31.1 million in 2023, then decreased by 1.45% to -$31.6 million in 2024, then tumbled by 31.29% to -$41.5 million in 2025, then retreated by 8.25% to -$44.9 million in 2026.
- Per Business Quant, the three latest VSTM Operating Income figures stand at -$44.9 million (Q1 2026), -$41.5 million (Q4 2025), and -$40.7 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Verastem | 166.09 Mn | -31.73 Mn | 15.90 Mn | -44.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.90 Mn |
| Dec 31, 2025 | -41.48 Mn |
| Sep 30, 2025 | -40.72 Mn |
| Jun 30, 2025 | -43.76 Mn |
| Mar 31, 2025 | -44.17 Mn |
| Dec 31, 2024 | -31.59 Mn |
| Sep 30, 2024 | -37.03 Mn |
| Jun 30, 2024 | -18.28 Mn |
| Mar 31, 2024 | -28.06 Mn |
| Dec 31, 2023 | -31.14 Mn |
| Sep 30, 2023 | -21.31 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.34 Mn |
| Dec 31, 2022 | -16.85 Mn |
| Sep 30, 2022 | -17.71 Mn |
| Jun 30, 2022 | -21.40 Mn |
| Mar 31, 2022 | -16.98 Mn |
| Dec 31, 2021 | -16.51 Mn |
| Sep 30, 2021 | -14.85 Mn |
| Jun 30, 2021 | -15.94 Mn |